Charles River’s Oncology Therapeutic leader, Julia Schüler, writes about the impact of the Cypre 3D tumor platform in assaying the tumor microenvironment, stating ”We now have a platform for robust and repeatable screening using high-content image analysis. The hope is that this will rapidly identify a pipeline of effective therapies that hold up in the clinic and make it to patients.”